Lisinopril Versus Hydrochlorothiazide in Obese Hypertensive Patients

Autor:	Efrain Reisin, Matthew R. Weir, Bonita Falkner, Howard G. Hutchinson, Deborah A. Anzalone, Michael L. Tuck for the Treatment in Obese Patients With Hypertension
Rok vydání:	1997
Předmět:	medicine.medical_specialty Ambulatory blood pressure business.industry medicine.medical_treatment Urology Lisinopril Hemodynamics Placebo Endocrinology Blood pressure Hydrochlorothiazide Internal medicine Internal Medicine medicine Diuretic business Thiazide medicine.drug
Zdroj:	Hypertension. 30:140-145
ISSN:	1524-4563 0194-911X
Popis:	Abstract Because obesity-associated hypertension has unique hemodynamic and hormonal profiles, certain classes of antihypertensive agents may be more effective than others as monotherapy. Thus, we compared the efficacy and safety of the angiotensin-converting enzyme inhibitor lisinopril and the diuretic hydrochlorothiazide in a 12-week, multicenter, double-blind trial in 232 obese patients with hypertension. Patients with an office diastolic pressure between 90 and 109 mm Hg were randomized to treatment with daily doses of lisinopril (10, 20, or 40 mg), hydrochlorothiazide (12.5, 25, or 50 mg), or placebo. Mean body mass indexes were similar for all patients. At week 12, lisinopril and hydrochlorothiazide effectively lowered office diastolic (−8.3 and −7.7 versus −3.3 mm Hg, respectively; P P P P P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a63e2b5710959e967d0746a124722758 https://doi.org/10.1161/01.hyp.30.1.140 Zobrazit plný text záznamu